Isomorphic Labs, an AI-first drug design and development company founded by DeepMind founder Sir Demis Hassabis, is reportedly raising $5 billion (£3.75bn) in fresh funding.
Isomorphic raised £1.6bn in Series B funding just this summer, following a $600m round completed in March.
It could be valued at $50bn (£37bn) by the fundraise if it completes on currently expected terms, according to Bloomberg.
Sir Demis expects the company’s first clinical trials to start before the end of the year.
Isomorphic Labs has developed a number of proprietary breakthrough AI models that together form its unified AI drug design engine that works across multiple therapeutic areas and drug modalities.
This year it published a subset of the powerful and expansive capabilities of its IsoDDE engine, highlighting its predictive accuracy and introducing new capabilities which bridge the gap between structure prediction and real-world drug discovery.
IsoDDE offers a scalable foundation for AI drug design, providing the predictive fidelity required to navigate novel biological systems with unprecedented accuracy.
The firm has a strong portfolio of strategic partnerships with industry leaders like Novartis, Lilly and Johnson & Johnson.
The company employs more than 350 staff across London, Cambridge, Massachusetts in the US and Lausanne, Switzerland.